Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells
derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with
chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).